Fresenius Kabi releases generic Cetrotide
Fresenius Kabi has launched cetrorelix acetate for injection kit.
Cetrorelix acetate for injection is a generic to EMD Serono’s Cetrotide (0.25 mg).
Cetrorelix acetate for injection is available immediately from Fresenius Kabi in a kit that contains one single-dose vial (0.25 mg cetrorelix), one pre-filled syringe with 1 mL sterile water for injection, one 20-gauge needle, and one 27-gauge needle.
“Our newest launch of cetrorelix acetate for injection further demonstrates Fresenius Kabi’s strength in broadening access to cost-effective injectable medicines and our commitment to women’s health,” said Arun Verma, president of Fresenius Kabi USA.
[Read more: Fresenius Kabi intros generic Cytoxan]
Cetrorelix acetate for injection is a prescription medicine used to block the effects of a natural hormone, called gonadotropin releasing hormone. During hormone treatment for ovarian stimulation, premature ovulation may lead to eggs that are not suitable for fertilization. Cetrorelix acetate for injection blocks such undesirable premature ovulation, the company said.
According to the American Society for Reproductive Medicine, the number of babies born from IVF increased from 89,208 in 2021 to 91,771 in 2022, reflecting a steady increase in demand for fertility services. The latest national data means that 2.5% of all births in the US are a result of successful Assisted Reproductive Technology (ART) cycles, Fresenius Kabi said.
Cetrorelix acetate for injection is the fourth product in Fresenius Kabi’s growing portfolio of Women’s Health products. This addition underscores Fresenius Kabi’s commitment to providing a comprehensive range of FDA-approved, cost-effective treatment options.
[Read more: Fresenius Kabi intros generic Tepadina]
Fresenius Kabi’s other Women’s Health products include Chorionic Gonadotropin for Injection, (hCG); progesterone injection; and ganirelix acetate injection. Fresenius Kabi plans to expand its Women’s Health portfolio, helping to meet the growing demand for reproductive health options in the United States.